Major Depressive Disorder (DSM-V) – Landscape & Forecast – Disease Landscape & Forecast

The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line treatments contributes to the challenges that branded therapies face when entering this market. Brand-only drugs (e.g., Lundbeck / Takeda’s Trintellix / Brintellix, Lundbeck / Otsuka Pharmaceutical’s Rexulti / Rxulti) largely compete for use in treatment-refractory patients. Janssen’s Spravato, one of the most recent entrants into the depression market, offers a fast onset of therapeutic effect compared with the approved therapies, an attribute that fulfills a key unmet need; however, its use for treatment-resistant depression is constrained by multiple factors. Owing to the remaining unmet need, physicians will continue to look to emerging therapies—many of which offer novel mechanisms of action—as potential future treatments in this market.


  • What is the size of the MDD therapy market in the G7 countries? What key events will influence the market over the next decade?
  • What is the epidemiology of MDD in the G7 countries? What percentage of prevalent patients are diagnosed and drug-treated?
  • What factors drive and constrain the use of branded antidepressants and atypical antipsychotics in MDD? Which branded therapy is expected to experience the most commercial success during the forecast period?
  • What are the greatest areas of unmet need in the treatment of MDD, and how are emerging therapies expected to address these unmet needs?


Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 34 country-specific interviews with thought-leading psychiatrists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of MDD by country; diagnosed / drug-treated prevalence of MDD by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key MDD therapies in 2022-2032, segmented by brands / generics.

Emerging therapies: Phase 3/PR: 8 drugs. Coverage of select early-phase products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports